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Abstract
Vaccination with a biologically active Tat protein or tat DNA contained infection with the highly pathogenic SHIV89.6P virus, preventing
CD4 T-cell decline and disease onset. Here we show that protection was prolonged, since neither CD4 T-cell decline nor active virus
replication was observed in all vaccinated animals that controlled virus replication up to week 104 after the challenge. In contrast, virus
persisted and replicated in peripheral blood mononuclear cells and lymph nodes of infected animals, two of which died. Tat-specific
antibody, CD4 and CD8 T-cell responses were high and stable only in the animals controlling the infection. In contrast, Gag-specific
antibody production and CD4 and CD8 T-cell responses were consistently and persistently positive only in the monkeys that did not
control primary virus replication. These results indicate that vaccination with Tat protein or DNA induced long-term memory Tat-specific
immune responses and controlled primary infection at its early stages allowing a long-term containment of virus replication and spread in
blood and tissues.
© 2004 Elsevier Ltd. All rights reserved.
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1. Introduction
Tat is a key viral regulatory protein of human immunode-
ficiency virus (HIV) produced very early after infection even
prior to provirus integration [1–3]. Tat is essential for viral
replication, transmission and disease progression [1,4–7].
In addition, Tat can modulate the expression of cytokines
and cellular genes [6–11], and chemokine receptors [12–15],
which are responsible for the transmission of macrophage-
and T-cell-tropic HIV-1 strains, respectively. In addition, the
Tat protein also plays key roles in viral pathogenesis and in
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the pathogenesis of acquired immune deficiency syndrome
(AIDS)-associated Kaposi’s sarcoma [8,16–22].
Several studies suggest that an immune response to Tat
has a protective role and may control the progression of the
disease in vivo. Specifically, antibody (Ab) responses to Tat
have been associated with non-progression to AIDS [23–28].
Similarly, anti-Tat CTLs have been shown to inversely cor-
relate with progression to AIDS [29,30]. Of importance,
Tat is conserved in its immunogenic regions among all M
subtypes, and Tat B clade is recognized to the same extent
by sera from South African, Ugandan and Italian individ-
uals infected with A, B, C and D virus clades [28]. Fur-
ther, studies in humans [29,30] and in monkeys indicate that
anti-Tat CTLs are key to control virus replication early af-
ter primary infection, and that they exert a selective immune
pressure on the virus leading to the appearance of slowly
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replicating and apparently less pathogenic escape mutants
[31].
Taken together, this body of evidence suggests that im-
munization with Tat may block HIV replication both in
individuals exposed to the virus after vaccination and in
seropositive patients, reducing HIV infection and favouring
its control by the mounting immune response. In this regard,
some features of the Tat protein are relevant to Tat-based
vaccine development. First, we have recently shown that bi-
ologically active native HIV-1 Tat protein, but not its oxi-
dized counterpart, is taken up very efficiently and selectively
by monocyte-derived dendritic cells and induces their mat-
uration and antigen presenting function, driving Th-1 type
immune responses [32]. Secondly, soluble Tat protein has
been shown to enter the major histocompatibility complex
(MHC) class I pathway of antigen presentation, leading to
elicitation of cytotoxic T lymphocytes (CTLs) [33].
Pre-clinical studies in mice and monkeys have shown that
vaccination with a biologically active native HIV-1 Tat pro-
tein or with tat DNA is safe [34–38], elicits both humoral
and cell-mediated Tat-specific immune responses [34–38],
and, in cynomolgus monkeys, controls infection with the
highly pathogenic SHIV89.6P virus, preventing CD4 T-cell
decline and disease onset in the protected animals [34–36].
Similar results of protection were reported in the SIV model
with viral vectors (Semliki Forest Virus and Modified Vac-
cinia Ankara Virus) expressing the SIV-Tat and -Rev genes
[39]. Of importance, injection of plasmid DNA coding for
the HIV-1 regulatory genes Nef, Rev and Tat was reported
to be safe and immunogenic in HIV-1 infected individuals
[40,41].
Since Tat vaccination does not prevent infection but
controls virus replication and disease onset, it is key to
investigate whether protection is long-lasting, and to deter-
mine the level of virus infection, reservoir, and replication
over time in the protected animals. Therefore, we extended
the analysis of the vaccinated and control macaques up to
2 years after the challenge, looking for signs of virus per-
sistence and replication in blood and lymph nodes and for
persistence and development of CD4 and CD8-mediated
immune responses to HIV-1 Tat and SIV Gag, respectively.
The results indicate that vaccination with either a biolog-
ically active Tat protein or tat DNA induces a long-term
protection (i.e. containment of infection) against challenge
with the highly pathogenic SHIV89.6P virus, which is asso-
ciated with the absence of detectable virus replication both
in blood and tissues and with the persistence of Tat-specific
T- (both CD4 and CD8) and B-cell memory responses.
2. Materials and methods
2.1. Vaccination protocol and virus challenge
Adult male cynomolgus monkeys (Macaca fascicularis)
were housed in single cages within level three biosafety fa-
cilities according to the European guidelines for non-human
primate care (EEC, Directive No. 86-609, 24 November
1986). Blood samples were obtained from the inguinal vein
while the animals were under ketamine hydrochloride anes-
thesia (10 mg/kg). Clinical examination and weight mea-
surement were performed at the time of blood collection. At
each time-point bleedings were performed for routine blood
chemistry tests and immunological determinations. The vac-
cination protocols and schedules have been reported else-
where [34–36]. After 14–18 weeks from the last boost, all
animals were challenged intravenously (i.v.) with 10 MID50
of the SHIV89.6P virus, a highly pathogenic SHIV contain-
ing the tat gene of HIV-1. The virus stock used was derived
from a cynomolgus macaque inoculated with the original
SHIV89.6P from rhesus monkeys [42]. Both the original vi-
ral stock grown in a rhesus macaque and the one grown in
a cynomolgus monkey were highly pathogenic in M. fasci-
cularis [34,35]. The pathogenicity in cynomolgus monkeys
of both virus stocks was confirmed by the progression to
AIDS and death (within 46 weeks from the inoculum) of
four out of six and four out of seven cynomolgus monkeys
infected, respectively, with the rhesus- or cynos-derived vi-
ral stock [35]. The two naive control animals, monkeys 2
and 12, included as additional control at the time of the chal-
lenge, were inoculated with a three-fold higher (28 MID50)
or three-fold lower (2.8 MID50) viral inoculum, respectively
[34–36].
2.2. Detection of anti-SIV and anti-HIV Env and p27 Gag
antigen in plasma
Ab titers to the whole SIV were determined by endpoint
dilution of plasma samples using a HIV-2 enzyme-linked
immunosorbent assay (ELISA) (Elavia AC-Ab-Ak II Kit,
Diagnostic, Pasteur) according to the manufacturer’s instruc-
tions. Ab titers against the HIV-1 Env were detected by an
HIV-1 ELISA assay (HIV-1/HIV-2 Third Generation Plus,
Abbott, Chicago, IL). The mean of the negative control plus
3 S.D. represented the cut-off value.
Levels of p27 Gag protein were measured in plasma by
using a capture ELISA assay (Innotest, Innogenetics, Zwi-
jndrecht, Belgium) with a detection limit of 20 pg/ml.
2.3. Quantitation of the SHIV RNA copies in plasma
Until week 14 post-challenge quantitation of SHIV89.6P
RNA copies was performed only in the Bayer-Chiron Di-
agnostics reference Testing Laboratory (Amsterdam, The
Netherlands) by a branched DNA (bDNA) signal amplifi-
cation assay recognizing the pol region of the SIVmac251
strain, as described [34], with a cut-off of 1,500 RNA
copies/ml. Between week 14 and 28 post-challenge quanti-
tation of SHIV89.6P RNA copies was performed by both
the bDNA method and by a more sensitive quantitative com-
petitive RNA-polymerase chain reaction (QC-RNA-PCR,
cut-off: 50 RNA copies/ml) as already described [43]. Since
3260 M.T. Maggiorella et al. / Vaccine 22 (2004) 3258–3269
week 35 post-challenge, quantitation of SHIV89.6P RNA
copies was performed only by QC-RNA-PCR.
2.4. Proviral DNA detection
DNA was extracted from whole blood using the QIAamp
Blood Kit (QIAGEN, GmbH, Hilden, Germany) or from
lymph node cells using the phenol–chloroform method, fol-
lowed by precipitation with 3 M sodium acetate and cold
ethanol. SHIV proviral copy number was determined by a
semi-quantitative DNA PCR utilizing 1g of DNA and am-
plifying a 496 bp region of the gag gene of SIVmac239, as
already described [34,36]. The lower limit of detection was
1 SHIV proviral copy/g of DNA.
2.5. Unintegrated virus DNA detection
For analysis of viral extrachromosomal circular DNA
(E-DNA), DNA was extracted from lymphocytes ((2–5) ×
106) using the QIAprep Spin Miniprep Kit in order to enrich
for the low molecular weight DNA fraction, and analyzed
by PCR for the presence of circular forms of viral DNA as
described [44,45]. Twenty microliters of the total volume
(50l) were denaturated at 95 ◦C for 5 min, and subjected
to 40 cycles of PCR with an annealing temperature of 60 ◦C
for 30 s, an extension temperature of 72 ◦C for 30 s and a
denaturation temperature of 95 ◦C for 30 s, using primers
FORN15′-GTGACTCCACGCTTGTTTGC-3′ (forward),
located in the R LTR region, and REVN15′-CTCCTGTGC-
CTCATCTGATACA-3′ (reverse), mapping in the U3 LTR
region of the SIVmac239. The amplified fragment was
361 bp in length. As positive control, a reference standard
was prepared by cloning the PCR product, amplified from
DNA of CEMx174 chronically infected with SHIV89.6P,
into the pCR 2.1 vector (Invitrogen, Carlsbad, CA).
Hybridization was performed according to established
procedures [46] utilizing the FORN1/REVN1 PCR product
as probe.
2.6. Virus isolation and cell associated viral load
(cytoviremia)
Virus isolation and cytoviremia were performed by
co-culturing CD8-depleted PBMCs with CEMx174 cells in
the presence of phytohemoagglutinin (PHA, 2g/ml) and
recombinant human interleukin-2 (rhIL-2) (50 IU/ml), as
already described [34–36].
2.7. Lymphocyte subsets determination
Citrated peripheral blood cells were stained with ph-
icoerythrin PE-conjugated anti-CD4 (Biosource Interna-
tional, Camarillo, CA) and peridin chlorophyll protein
(PerCP)-conjugated anti-CD8 mAb (Becton-Dickinson,
Mountain View, CA), and analyzed with a FACScan cy-
tometer and software (Becton-Dickinson) as described
[34,36]. Absolute cell numbers were calculated from blood
cell counts.
2.8. Recombinant proteins
The Tat protein (1–86 aa) from the HTLV-IIIB isolate,
BH-10 clone (clade B), was expressed in E. coli, purified
and stored as described earlier [9,32,34]. The purified Tat
protein was fully monomeric and had full biological activ-
ity as assessed by virus transactivation assays and by uptake
studies in monocyte-derived dendritic cells [6,9,32,34]. Tat
used for in vitro studies was resuspended in degassed buffer
before use as described [6,28,34]. The SIVmac251 p55 Gag
recombinant protein was derived from baculovirus was ob-
tained through Quality Biological, Inc. and the Vaccine Re-
search and Development Branch, Division of AIDS, NIAID,
NIH (Bethesda, MD).
2.9. T-cell proliferation assays
To evaluate the proliferative response to Tat, Gag and the
recall antigen tetanus toxoid (TT), Ficoll-purified PBMCs
(2 × 105 per well) were seeded in flat bottomed 96-well
microtiter culture plates in triplicates in a final volume of
200l of RPMI containing 10% FCS (medium) and cul-
tured either alone or in the presence of PHA (2g/ml),
TT (5g/ml, Connaught, Ontario, Canada), Tat protein
(5 mg/ml), SIVmac251 p55 Gag protein (5 mg/ml) or SIV-
mac239 p27 Gag 15mers peptides (aminoacid 226–240,
231–245, 236–250, 283–297, 289–303, 295–309 at 5 mg/ml
each) or buffer [phosphate buffered saline (PBS) containing
0.1% BSA]. After 5 days of incubation at 37 ◦C in 5% CO2,
cell cultures were pulsed with 1Ci/well of [3H]thymidine
(Amersham Life Science, Buckingamshire, UK) and the
incorporated radioactivity was measured 18 h later, as pre-
viously described [34,36]. A stimulation index (SI) ≥3 was
considered positive.
2.10. Interferon (IFN)-γ ELISpot assay
The number of IFN- producing cells (spot forming
cells, sfc) was measured by a commercial kit (Human
IFN- ELISpot, Euroclone, Paignton, UK), following the
manufacturer’s instructions. Briefly, PBMCs (2 × 105 per
well, in duplicate) were cultured with medium alone or in
the presence of PHA (2g/ml), TT (5g/ml), Gag or Tat
protein (5g/ml), or buffer in flat bottomed 96-well plates
previously coated with a mAb to IFN-. After 18 h, cells
were removed and locally produced IFN- was revealed by
an immunoenzymatic reaction into a gel matrix as coloured
spots. The spots, a measure of IFN- producing cells, were
counted under a light microscope and expressed as num-
ber of sfc per 106 PBMCs upon subtraction of background
counts. Based on data obtained with PBMCs from 24 naive
monkeys, a number of sfc greater than 20/106 cells was
considered as a positive response to the antigen.
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2.11. Lymph node biopsies
Inguinal lymph nodes were removed surgically under ke-
tamine hydrochloride anesthesia at week 55 after challenge
from monkeys vaccinated with the pCV-tat, and at week 71
after challenge from monkeys vaccinated with the Tat pro-
tein and from control monkeys. The tissue was minced to
obtain single cell suspension for virus isolation, quantitative
detection of proviral DNA, and analysis for the presence of
E-DNA forms, which were performed as described above.
2.12. Statistical analyses
The statistical significance of the differences between vac-
cinated and control monkeys during the course of infection
was determined by the Fisher’s exact test for quantitation
of SHIV RNA copies in plasma and for SHIV DNA PCR
and E-DNA analyses in lymph node biopsies. The Student’s
t-test for independent samples was used to assess differences
between groups concerning the proliferative response and
the IFN- ELISpot to Tat and Gag antigens.
3. Results
3.1. Long-term containment of virus replication in
vaccinated and protected animals
A total of 12 macaques were vaccinated with the Tat pro-
tein or the pCV-tat plasmid as two arms of the same pro-
tocol and challenged i.v. with SHIV89.6P, as reported in
Section 2. The results of the immune response to Tat before
the challenge, challenge outcome and virological data up
to 46 weeks after challenge have been published elsewhere
[34–36]. These results indicated that, although vaccination
with the biologically active Tat protein or pCV-tat did not
prevent virus entry, it contained primary infection in 9 out
of 12 vaccinated animals. Therefore, the term protection,
as used in the present study, refers to protection from virus
replication and disease onset, that is control of infection, and
not to prevention of infection. Consequently, animals were
defined as controllers or non-controllers according to their
virological status early after challenge.
To investigate whether control of infection was durable,
all macaques (both vaccinated and controls) were monitored
up to 104 weeks after the challenge for plasma viremia,
circular viral DNA, proviral DNA and virus isolation both
in blood and lymph nodes.
As shown in Fig. 1, plasma viremia remained undetectable
in all (9/12) animals, which controlled primary virus repli-
cation (vaccinated and protected animals), whereas in the
three vaccinated animals unable to control virus replication
(monkeys 54963, 55396, and 37) plasma viremia either be-
came undetectable early in the follow-up (week 23 for mon-
key 54963), or remained detectable with a further increase
late in the follow-up (monkeys 55396 and 37) (Fig. 1A and
B). Viral RNA was also detected over time in all adjuvant
control and naive control macaques. In particular, monkey
2 had high levels of viral RNA up to week 35 when was
euthanised due to AIDS (Fig. 1C). Similarly, monkey 37
died of AIDS at week 75 after challenge. The comparison
of plasma viremia data between vaccinated and control an-
imals at week 4 after challenge revealed a statistically sig-
nificant difference, as determined by the Fisher exact test
(P-value = 0.019).
To better evaluate virus replication, E-DNA, a param-
eter more sensitive than the evaluation of plasma viremia
[44,45], was measured in PBMCs of all macaques (with the
exception of monkey 2) and compared with plasma viremia
at early and/or late time points post-challenge (Fig. 1). A
good correlation was observed between the presence of
E-DNA and plasma viremia. However, E-DNA was also
found in animals with undetectable plasma viremia, indicat-
ing the presence of low levels of persistent viral replication.
In particular, E-DNA was positive at multiple time points
post-challenge in all the non-controllers, both viremic and
aviremic, whereas it was detected only once in three out
of the nine controllers (plasma viremia always below the
detection threshold) (Fig. 1).
The frequency of viral isolation also correlated with the
presence of viral RNA in plasma. In fact, the virus was
not isolated from any of the macaques controlling infection,
even after depletion of the CD8+ T-cells. Conversely, it was
frequently isolated from all the non-controllers ([34–36],
and data not shown).
Similarly, after the challenge the provirus was either un-
detectable or sporadically present at a very low level (<10
copies/g of DNA) in the controllers, and always detected
in all the non-controllers (Fig. 2A–C).
Consistent with the virological data, in all the controllers
the number of CD4+ T-cells was in the normal range during
the entire follow-up (104 weeks). In contrast, it decreased
considerably in all the non-controllers (3/12 vaccinated and
4/4 control macaques) (Fig. 3A–C). In particular, monkeys
2 and 37 had a sharp and profound CD4+ T-cell decline,
developed AIDS and died.
Taken together, these results indicated that vaccinated and
protected monkeys contained virus infection and replication
during the all post-challenge follow-up (104 weeks). In con-
trast, all infected animals had higher levels of latent infec-
tion and showed a persistent virus replication in blood.
3.2. Absence of a virus reservoir and virus replication in
lymph nodes of vaccinated and protected macaques
Since lymph nodes are a major virus reservoir, virus iso-
lation and determination of integrated or unintegrated viral
DNA were performed late after the challenge on lymph
node biopsies (week 55 for the monkeys vaccinated with
the pCV-tat and week 71 for monkey vaccinated with the
Tat protein, the control monkeys and the naive monkey
12) and compared with the results obtained with PBMCs
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Fig. 1. Plasma viremia and E-DNA in PBMCs up to week 104 after the challenge with SHIV89.6P. (A) Tat protein vaccinated monkeys; (B) tat DNA
vaccinated monkeys; (C) adjuvant control and naive control monkeys. The dashed area indicates the cut-off value of 1500 RNA copies/ml until week
14, and of 50 RNA copies/ml from 18 to 104 weeks. E-DNA determinations were performed at the indicated weeks. The signs (−), negative and (+),
positive, indicate the absence or presence of E-DNA, respectively.
of the same time points (data not shown). All the vacci-
nated animals controlling infection (9/12) were negative for
virus isolation, proviral DNA and E-DNA in both PBMCs
and lymph nodes (Figs. 1 and 2, and data not shown).
Among the non-controllers the vaccinated monkeys 55396
and 37 were positive for all assays in both PBMCs and
lymph nodes, whereas monkey 54963 was negative for
virus isolation in both PBMCs and tissues. In addition, this
latter animal had a proviral load higher in lymph nodes
(47 copies/g DNA) than in PBMCs (1 copy/g DNA),
although E-DNA forms were found only in PBMCs. Con-
cerning the control macaques, all overtly infected, lymph
nodes from the adjuvant control animals 55123 and 55129
and the naive control monkey 12 were positive for both
proviral DNA (43, 5, 36 copies/g DNA, respectively) and
E-DNA. The differences of either proviral DNA or E-DNA
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Fig. 2. Proviral DNA copies in PBMCs up to week 104 after the challenge with SHIV89.6P. (A) Tat protein vaccinated monkeys; (B) tat DNA vaccinated
monkeys; (C) adjuvant control and naive control monkeys.
levels in lymph nodes of vaccinated (both protected and
overtly infected) macaques versus control monkeys were
statistically significant (Fisher’s exact test: P-value = 0.04
and 0.02, respectively).
3.3. Containment of infection is associated with stable
Tat-specific CD4 and CD8 T-cell responses
To determine whether Tat-specific immune responses
were durable and whether they correlated with protec-
tion, antibodies, lymphoproliferative response and IFN-
ELISpot against Tat were evaluated in all animals at several
time points during the follow-up.
Before challenge, anti-Tat IgG titers were high in the
monkeys immunized s.c. with the Tat protein and RIBI or
Alum adjuvant, low or undetectable in the other vaccinated
animals [34–36]. After challenge, anti-Tat IgG titers were
stable up to week 14, declined thereafter, and remained de-
tectable up to week 104 only in the monkeys vaccinated s.c.
with the Tat protein and RIBI or Alum (Table 1, and data
not shown). Thus, exposure to the challenge virus did not
result in the induction of anti-Tat antibodies. However, they
remained detectable through the all follow-up time in those
animals that had developed high titers in response to the Tat
vaccine (Table 1, and data not shown).
Proliferative responses to Tat were detected in most vac-
cinated monkeys before challenge [34–36]. Early after chal-
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Fig. 3. CD4 T-cell counts up to week 104 after the challenge with SHIV89.6P. (A) Tat protein vaccinated monkeys; (B) tat DNA vaccinated monkeys;
(C) adjuvant control and naive control monkeys.
lenge (Table 1, and results not shown), they were high and
persistent in all the macaques vaccinated with Tat and RIBI
or Alum, lower and sporadic in the monkey vaccinated i.d.
with the Tat protein alone and in those immunized with 1 mg
of pCV-tat, whereas no responses were detected in monkeys
PR2 and 37 that had received 0.5 and 0.2 mg of pCV-tat,
i.m. and i.d., respectively. Late after challenge (Table 1, and
results not shown), lymphoproliferative responses to Tat in-
creased in four out of five macaques vaccinated with the
Tat protein and protected, while they became detectable, al-
though sporadically, in the three monkeys immunized with
1 mg of pCV-tat. Among the non-controllers a sporadic lym-
phoproliferative response was detected in monkeys 55129
(control Alum), and 55123 (control RIBI), whereas in the
vaccinated and infected animals (monkeys 54963, 55396,
and 37) no proliferative response to Tat was detected.
IFN- ELISpot assay to Tat was positive in eight out of
the nine protected macaques (Table 1, and data not shown).
Of interest, the highest and most persistent responses were
detected in the monkeys vaccinated with Tat and RIBI, in-
cluding the animal that did not control infection (monkey
54963). Of note, in this latter macaque a strong response
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Table 1
Humoral and cellular immune responses to HIV-1 Env and Tat and SIV Gag early and late after challenge with SHIV89.6P in vaccinated and control animals divided in controllers and non-controllers
according to the virological status
Monkey Group Immune response early (up to week 23) after challenge Immune response late (week 55–104) after challenge
Antibodies to Anti-Tat immune
responses
Antibodies to Anti-Gag immune
responses
Anti-Tat immune responses
HIV Enva SIVa IgGa Proliferative
responseb
HIV Enva SIVa Proliferative
responseb
IFN-
ELISpotc
IgGa Proliferative
responseb
IFN- 
ELISpotc
Controllers
54844 RIBI + Tat (10g, s.c.) +∗ − ++ ++ − − − − ++ ++ +
54879 +∗ − +++ ++ − − ± − ++ +++ ++
54899 ALUM + Tat (10g, s.c.) +∗ − ++++ + − − − − ++ +++ +
54240 +∗ − +++ + − − + − + ++ +
54222 Tat (6g, i.d.) +∗ − ± − − − ++ + − +++ +
54920 pCV-tat (1 mg, i.m.) −∗ − ± − − − ± − − ± −
55122 +∗ − + − − − − − − ± +
55361 +∗ − − − − − ± − − − +
PR2 pCV-tat (0.5 mg, i.m.) −∗ − − − − − − − − − +
Non-controllers
54963 RIBI + Tat (10g, s.c.) ± + +++ ++ + ++ + + ++ ++ ++
55396 ALUM + Tat (10g, s.c.) + ++ +++ + +++ +++ ++ + + + −
37† pCV-tat (0.2 mg, i.d.) + ++ + − +++ ++ ± ND − − ND
55123 Control RIBI + +++ − − ++ +++ ± + − ± −
55129 Control ALUM + ++ − − + ++ +++ + − ± −
12 NIL + ++ ND ND +++ +++ ND − ND ND −
2† NIL + − ND ND ND∗∗ ND∗∗∗ ND ND ND ND ND
† Monkeys 2 and 37 could not be analyzed since they were euthanized at week 35 and 75 post-challenge, respectively. ND, not done.
a Antibody titers to HIV-1 Env, HIV-1 Tat, and SIV Gag. Reciprocal of the last positive dilution was expressed as: −, <10; ±, 10–50; +, 51–400; ++, 401–3200; +++, 3201–12,800; ++++,
>12,800.
b Stimulation index (ratio between antigen-specific and control proliferative response): −, S.I. <3; ±, S.I. ≥3 in 33–50% of determinations; +, S.I. ≥ 3 in > 50% of determinations; + +, S.I. ≥3
in > 50% of determinations with S.I. peak value between 10 and 30; +++, S.I. ≥3 in >50% of determinations with S.I. peak value >30.
c Data are reported as the mean number of spot forming cells (SFC) per million PBMCs, detected after 18 h of stimulation with Tat or Gag protein (5g/ml), respectively, after substraction of
background counts. On the base of data obtained with PBMCs from 24 naive animals a test was considered positive when the number of SFC was greater than 20 per million PBMCs. Arbitrary
scoring (SFC per million PBMCs): −, <20; +, 20–100; ++, >100.
∗ Anti-HIV Ab detected by IVAP in the supernatants of PBMCs stimulated with PWM.
∗∗ ++, at the time of sacrifice (week 35).
∗∗∗ −, at the time of sacrifice (week 35).
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to Tat correlated with negative virus isolation and no de-
tectable virus replication (E-DNA) in lymph nodes. In con-
trast, in monkey 55396 (Tat + Alum), from which virus was
frequently isolated, no production of IFN- in response to
Tat was detected. Similarly, none of the adjuvant control or
naive control animals produced IFN- in response to Tat.
Thus, late after challenge eight out of nine controllers pro-
duced IFN- in response to Tat, as compared to one out of
the five non-controllers tested.
Overall, the Tat-specific proliferative and IFN- ELISpot
responses were higher and more frequent in the animals that
controlled infection and either sporadic, absent, or lost over
time in the monkeys unable to contain primary infection.
3.4. Immune responses to structural SIV/HIV antigens
in protected monkeys reveal a pattern suggestive of an
abortive infection
During the follow-up the Ab against SIV antigens or the
HIV envelope became undetectable in the controllers, which
showed very low titers (<1:10) early after challenge. Con-
versely, anti-SIV and anti-HIV Env titers remained high
or increased in the non-controllers (Table 1, and data not
shown). Similarly, lymphoproliferative responses to the Gag
protein or to a pool of Gag peptides were absent or sporadic
in 7/9 of the controllers (Table 1, and data not shown). In
contrast, three out of the six non-controllers analysed had
higher and persistent responses. This difference was statis-
tically significant (Student’s t-test P < 0.05).
IFN- ELISpot assay against Gag were positive in 1/9
vaccinated and protected monkeys and in four out of the
five non-controllers analyzed. Of note, a direct correlation
was found between IFN- production and the frequency
of virus isolation. The difference between the mean values
of Gag-specific IFN- secreting cells detected in the con-
trollers versus the non-controllers was statistically signifi-
cant (Student’s t-test: P-value <0.05).
Thus, robust and persistent Gag-specific B- and T-cell
responses were detected only in animals unable to control
virus replication. In contrast, they were low, transient or un-
detectable in all the vaccinated animals containing primary
virus replication. This pattern is suggestive of an abortive
infection in protected animals.
4. Discussion
Vaccination with a biologically active Tat protein or
pCV-tat controlled infection with the highly pathogenic
SHIV89.6P preventing CD4 T-cell decline and disease
onset. Here we show that protection after challenge was
prolonged since no CD4 T-cell decline nor active virus
replication was detected in all protected animals neither in
blood nor in lymph nodes for the entire follow-up period
(104 weeks). In addition, Tat vaccination elicited long-term
memory T-cell responses in the absence of any vaccine
boosting.
Containment of viral load is considered a critical param-
eter in the assessment of vaccine efficacy [47–50], since
high levels of viral load early after infection can be predic-
tive of disease progression [43,51–58]. Indeed, in the vac-
cinated and protected monkeys from this study, viral load
(either cell- or plasma-associated) was persistently low or
undetectable and CD4 T-cell decline did not occur. These
data were confirmed by the determination of unintegrated
forms of DNA, a very sensitive marker for active viral repli-
cation [59] as compared to plasma viremia [44,45]. In our
study, detection of circular E-DNA correlated with the pres-
ence of a detectable plasma viremia during the acute phase
of infection, in agreement with previous reports in both the
HIV [60,61] and the SIV model [62]. In fact, in the mon-
key model the presence of circular E-DNA was found to
correlate with low CD4:CD8 ratio in lymphoid organs and
with AIDS development [62]. Noteworthy, while plasma
viremia became undetectable, circular E-DNA remained de-
tectable during chronic infection in the non-controllers indi-
cating persistency of an active infection. In contrast, E-DNA
was detected only once in PBMCs from 3/9 protected ani-
mals. The results of virus containment were confirmed by
the analyses of lymph node biopsies showing undetectable
proviral DNA, virus isolation and circular viral DNA in all
the controllers, whereas one or more of these viral parame-
ters were positive in the non-controllers. Finally, two of the
seven non-controllers showed severe worsening of the clin-
ical conditions and died.
Immune responses to the viral antigens showed a differ-
ent and opposite pattern in the two groups of animals. In
particular, Tat-specific CD4 and CD8 T-cell responses (pro-
liferative response and IFN- ELISpot, respectively) were
consistently detected in all the controllers, as compared to
the non-controllers (vaccinated, adjuvant controls or naive
controls) in which they were absent or transient. Vice versa,
CD4 and CD8 T-cell responses to Gag were generally high
and persistent in the non-controllers, whereas they were un-
detectable or low and transient in the protected vaccinees.
Thus, the presence of CD4 and CD8 T-cell responses to Gag
correlated significantly with active virus replication.
The relevance of CTL responses against HIV-1 and SIV
early regulatory proteins Tat, Rev and Nef has been ad-
dressed in recent reports aimed at defining the role of CTLs
in controlling viremia and the factors governing the selec-
tion of escaping mutants, the only parameter presently avail-
able to measure CTLs efficacy. In a SIV model utilizing a
molecular clone for the challenge, a strong correlation was
found between the resolution of plasma viremia and the de-
tection of a dominant CTL response against a Tat epitope
(Tat28–35SL8) leading to the appearance of viral variants
with an apparently reduced fitness [31]. Subsequent studies
demonstrated that CTLs with high functional avidity for the
early and intermediate proteins Tat, Nef and Vpr were the
major factor driving the selection of immune escape vari-
ants during acute SIV infection [63]. More recent data mea-
suring inhibition of HIV-1 replication by CTLs clones with
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known avidity and specificity indicate that, in vitro, the fine
epitope specificity might be the most important factor at de-
termining control of virus replication and selection of virus
variants [64]. In both cases, CTLs against regulatory pro-
teins were responsible of rapid selection of escape variants
indicating a strong immune pressure. It has been proposed
that because of their early expression, targeting regulatory
proteins, rather than structural antigens, may be extremely
advantageous to the host because CTLs will impact on the
virus replication cycle at a critical step and for a prolonged
time [65]. Therefore, vaccines aimed at eliciting a large num-
ber of polyclonal CTLs against these antigens may prove ef-
fective at blocking virus expression during the early phases
of the acute infection, minimizing the selection of escape
variants. Along this line, a novel vaccine approach based on
a polyvalent chimeric protein in which the genes coding for
HIV-1 Tat, Rev and Nef has been recently developed and
found safe and immunogenic in macaques [66].
It is tempting to speculate that in our study vaccination
with either Tat protein or tat-DNA controlled primary infec-
tion at its early stages allowing containment of virus spread
in blood and tissues to undetectable levels, which were suf-
ficient to ensure development and maintenance of long-term
anti-Tat memory and to elicit weak anti-Gag T-helper but
not CTL responses in the protected monkeys. This pattern of
immune responses, together with the virological data, sug-
gests that in vaccinated and protected animals infection oc-
curred, but it was abortive. In addition, it suggests that im-
mune responses to Gag are not necessary to ensure long-term
protection in monkeys that have contained infection early
after challenge. However, development of anti-Gag humoral
and cellular immune responses in overtly infected monkeys
(non-controllers) may contribute to lower the viral load and
partially restore the CD4 T-cell number over time, mim-
icking the transitory control that marks the resolution of
the acute phase in the natural history of HIV-1 infection
in humans.
Recently, results have been reported showing that the im-
munization of rhesus monkeys with the Tat protein [67,68]
was safe and immunogenic but failed to induce a significant
control of viral replication following challenge with SIV or
SHIV89.6P pathogenic viruses. However, several and key
differences in the study design including dose and type of Tat
(SIV and HIV), monkey species, adjuvant, dose and sched-
ule of immunization, virus dose and route of challenge may
account for these conflicting results. Another key difference
may be represented by the conformation of the Tat protein.
Specifically, we found that small differences in Tat which
can be detected only by analytical HPLC and by uptake by
dendritic cells (and not by other assays), make important
differences in the targeting and effects of Tat on dendritic
cells which are key to initiate proper immune responses
([32], and unpublished data). Further, our results are in
agreement with reports from pre-clinical [39,69] and clini-
cal [40,41] trials indicating that vaccination with Tat is safe,
immunogenic and effective at controlling virus replication
and disease progression in the monkey model. These data
suggest that a native Tat protein or tat DNA should be in-
cluded in future vaccine designs, particularly in prime-boost
regimens. Based on these data, and on our recent results
from field studies in Africa indicating cross-clade recogni-
tion of Tat by anti-Tat Ab [28], preventive and therapeutic
phase I trials are currently under way in Italy. In addition,
a second generation of vaccine approaches combining Tat
with other antigens, such as Env and Gag, are under de-
velopment to verify whether a rationally designed antigen
combination can increase efficacy and long-term protection
against homologous as well as heterologous virus clades.
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